Archive

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""]The Epidermal Sensitization Assay (EpiSensA) is a next-generation, GLP-compliant method developed by the KAO Corporation. The EpiSensA offers a reliable, human-relevant method for assessing skin sensitization potential, enhancing our ability to provide New Approach Methodologies (NAMs)-based solutions that address industry challenges. The EpiSensA quantifies the changes in the expression of genes associated with the activation of keratinocytes and cytoprotective pathways, corresponding to the second key event (KE-2) in the skin sensitization Adverse Outcome Pathway.

  IIVS is excited about meeting attendees of the 55th EUROTOX conference! Please join us at booth #34 to meet our representatives who are looking forward to discussing trends and New Methodologies in Alternative Approaches (NAMs) to toxicological research, as well providing updates on services offered...

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text]KeratinoSensTM is a cell-based reporter gene assay that models the second key event in the Adverse Outcome Pathway for Dermal Sensitization  (keratinocyte activation). The assay measures the induction of a stably transfected luciferase gene under the control of the antioxidant response element (ARE) derived from the human AKR1C2 gene.

By Amanda Lim, Editor (Singapore) CosmeticsDesign-Asia.com   Although China has made significant strides in moving away from animal testing, its challenges suggest it may take more than five years for the country to completely stop compulsory animal-testing for cosmetics, says Hedy He, regulatory analyst and editor of ChemLinked:...